Our R&D
At Polfarmex, we believe that knowledge makes it possible to discover the world. It allows us to provide assistance when the most precious thing – health – is compromised. This is made possible by the power that comes from science.
Our research and development activities are based on 4 pillars:
- Developing preparations that are currently unavailable in the Polish market.
- Creating added value for the products offered by Polfarmex through work on immediate-release and modified-release dosage forms.
- Developing a line of inhalation products based on acquired knowledge and over 10 years of experience in the production of multi-dose powder inhalers.
- Advancing research on biosimilars.
RESEARCH AND DEVELOPMENT
The areas of our particular interest include:
Diseases of the lungs and respiratory system
Cardiovascular diseases
Metabolic diseases
Neurological diseases
Our ambition is to develop, register and introduce products that are first or second generics of reference drugs.
Did you know…?
We were the first in Poland to launch the first generic drug with modified-release indapamide, which lowers blood pressure, and we provided patients struggling with bronchial asthma or chronic obstructive pulmonary disease with the first generic drug containing a combination of fluticasone and salmeterol.
RESEARCH AND DEVELOPMENT DEPARTMENT
This is where our specialists in medicine, pharmacy, chemistry and biotechnology develop modern drug formulations, conduct research on their patent purity, and perform medical evaluations.
Our research and development activities include preparing documentation for clinical trials, developing analytical methods, pharmaceutical technologies, and creating registration documentation for medicinal products.
We have laboratories equipped with the latest analytical equipment and devices for the production of finished dosage forms on a laboratory and semi-technical scale. All of this is to ensure the high quality of our drugs in accordance with the Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP) standards.
Additionally, as part of the pharmacovigilance system for monitoring the safety of medicinal products, we conduct monitoring of the safety of pharmacotherapy.